Cargando…

Bone turnover markers in patients with type 1 Gaucher disease

Bone complications occur frequently in Gaucher disease (GD) and reduce the quality of life of these patients. Skeletal involvement is an important indication for treatment to ameliorate symptoms and reduce the risk of irreversible and debilitating disease. Bone biomarkers have been used to assess di...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giuffrida, Gaetano, Cingari, Maria Rocca, Parrinello, Nunziatina, Romano, Alessandra, Triolo, Anna, Franceschino, Magda, Di Raimondo, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PAGEPress Publications 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3555209/ https://www.ncbi.nlm.nih.gov/pubmed/23355939 http://dx.doi.org/10.4081/hr.2012.e21

Ejemplares similares

Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report
por: Giuffrida, Gaetano, et al.
Publicado: (2016)

PB2072: CIRCULATING CD71+ MYELOID PRECURSORS IN MGUS AND MULTIPLE MYELOMA: A PROSPECTIVE SURVEY
por: Parrinello, Nunziatina Laura, et al.
Publicado: (2023)

PB2093: OVERALL SURVIVAL IN RELAPSED-REFRACTORY MYELOMA PATIENTS DEPENDS ON CIRCULATING PLASMA CELLS QUANTITATION
por: Parrinello, Nunziatina Laura, et al.
Publicado: (2023)

Single segment of spleen autotransplantation, after splenectomy for trauma, can restore splenic functions
por: Toro, Adriana, et al.
Publicado: (2020)

P931: PROSPECTIVE OBSERVATIONAL MULTICENTER STUDY OF GAUCHER DISEASE PREVALENCE IN PATIENTS AFFECTED BY MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE
por: Giuffrida, G., et al.
Publicado: (2022)

Immunological Deregulation in Classic Hodgkin Lymphoma
por: Romano, Alessandra, et al.
Publicado: (2014)

Immunological Dysregulation in Multiple Myeloma Microenvironment
por: Romano, Alessandra, et al.
Publicado: (2014)

Lenalidomide and Pomalidomide Improve Function and Induce FcγRI/CD64 in Multiple Myeloma Neutrophils
por: Romano, Alessandra, et al.
Publicado: (2021)

Salvage Therapy of Multiple Myeloma: The New Generation Drugs
por: Romano, Alessandra, et al.
Publicado: (2014)

PB1993: EXPRESSION OF NEO-201 MAY HELP IN THE DIFFERENTIAL DIAGNOSIS BETWEEN MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA
por: Duminuco, Andrea, et al.
Publicado: (2023)

Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives
por: Romano, Alessandra, et al.
Publicado: (2019)

A case of high‐risk AML in a patient with advanced systemic mastocytosis
por: Fazio, Manlio, et al.
Publicado: (2023)

Immunological Subsets Characterization in Newly Diagnosed Relapsing–Remitting Multiple Sclerosis
por: D’Amico, Emanuele, et al.
Publicado: (2022)

Circulating markers of bone turnover
por: Vervloet, Marc G., et al.
Publicado: (2017)

The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents
por: Romano, Alessandra, et al.
Publicado: (2017)

Serum free light chains and multiple myeloma: Is it time to extend their application?
por: Markovic, Uros, et al.
Publicado: (2020)

Myeloid Derived Suppressor Cells (MDSCs) Are Increased and Exert Immunosuppressive Activity Together with Polymorphonuclear Leukocytes (PMNs) in Chronic Myeloid Leukemia Patients
por: Giallongo, Cesarina, et al.
Publicado: (2014)

Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC)
por: Giallongo, Cesarina, et al.
Publicado: (2016)

Gaucher disease – bone involvement
por: Chis, Bogdan Augustin, et al.
Publicado: (2021)

The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma
por: Romano, Alessandra, et al.
Publicado: (2016)

Impact of SARS-CoV-2 infection on Gaucher disease patients in Italy
por: Cappellini, Maria Domenica, et al.
Publicado: (2021)

Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells
por: Tibullo, Daniele, et al.
Publicado: (2015)

Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies
por: Palumbo, Giuseppe Alberto, et al.
Publicado: (2019)

Bone events and evolution of biologic markers in Gaucher disease before and during treatment
por: Stirnemann, Jérôme, et al.
Publicado: (2010)

The first description of a singular case of synchronous chronic myelomonocytic leukemia and diffuse large b‐cell lymphoma
por: Romano, Alessandra, et al.
Publicado: (2021)

Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacitidine in High-Risk Myelodysplasia
por: Romano, Alessandra, et al.
Publicado: (2017)

Zinc Intake and Biochemical Markers of Bone Turnover in Type 1 Diabetes
por: Maser, Raelene E., et al.
Publicado: (2008)

Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry
por: Rosenbloom, Barry E., et al.
Publicado: (2022)

P43 CIRCULATING CLONAL PLASMA CELLS AT START OF SALVAGE REGIMEN PROVIDE POWERFUL PROGNOSTICATION BIOMARKER IN MULTIPLE MYELOMA PATIENTS AT FIRST RELAPSE
por: Romano, A., et al.
Publicado: (2023)

Gaucher Disease and Gaucher Cells
por: Gözdaşoğlu, Sevgi
Publicado: (2015)

Bone Turnover Markers and Bone Mineral Density in Children with Hypophosphatemic Rickets
por: Michałus, Izabela, et al.
Publicado: (2022)

Bone Turnover Markers and Osteoprotegerin in Uncomplicated Pregnancy
por: Styczynska, Hanna, et al.
Publicado: (2009)

Metabolomic Associations with Serum Bone Turnover Markers
por: Bellissimo, Moriah P., et al.
Publicado: (2020)

Variation of Bone Turnover Markers in Childhood and Adolescence
por: Zhang, Yiduo, et al.
Publicado: (2023)

Changes in bone turnover markers and bone modulators during abatacept treatment
por: Adami, Giovanni, et al.
Publicado: (2023)

Use of Bone Turnover Markers in Clinical Practice for the Management of Osteoporosis in Korea: From the Survey on the Prescription Pattern of Bone Turnover Markers
por: Ahn, Seong Hee, et al.
Publicado: (2019)

Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients
por: Giallongo, Cesarina, et al.
Publicado: (2016)

Monocytic myeloid‐derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib
por: Giallongo, Cesarina, et al.
Publicado: (2017)

Parkinson’s disease in Gaucher disease patients: what’s changing in the counseling and management of patients and their relatives?
por: Di Rocco, Maja, et al.
Publicado: (2020)

In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection
por: Romano, Alessandra, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_muduterc5c8c22cknvpuursi7e